Agilent Expands Access to Incyte Database and Patents to Boost Custom Array Business | GenomeWeb

NEW YORK, Sept. 17 — Agilent and Incyte said today that they would expand an existing licensing agreement to enable Agilent to offer a more comprehensive range of catalog and custom microarrays using Incyte’s gene patent portfolio and  genomic  databases. Using Incyte’s LifeSeq products, Agilent said it would develop highly specific cDNA- and oligonucleotide-based microarrays. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.